

STRONG SALES IN THE 3RD QUARTER OF 2010

October 19, 2010 (Lure, France) – Vétoquinol's revenues for the third quarter of 2010 rose by 10.8%. This healthy rate of growth was attributable mainly to strong performance in the Group's strategic regions and therapeutic segments.

<i>in thousands of euros</i>	3rd quarter 2010	3 rd quarter 2009	Change
Revenues	68,869	62,168	+10.8%
Revenues <i>at constant exchange rates</i>	65,367	62,168	+5.2%
Revenues <i>at constant exchange rates and business scope</i>	64,723	62,168	+4.1%

Strong performance

Vétoquinol generated revenues of €68.9 million in the third quarter of 2010, an increase of 10.8% compared with the same period in the preceding year, or 5.2% when exchange rates are held constant. Thus, with the decline in the value of the euro, exchange rates had a positive effect of 5.6%. Organic growth for the first nine months of 2010 stood at 5.4%, exceeding the targets of our economic model for the medium term.

Strong 3rd quarter

Despite a less favourable basis effect in the 3rd quarter, sales remained strong:

- Sales for companion animals and livestock increased by 8.7% and 13.0% respectively;
- Sales in the Group's three strategic therapeutic segments (anti-infectives, pain/inflammation and cardiology/nephrology) increased by 10.3%;
- In geographic terms, growth was driven primarily by strong performance in Asia/Pacific and the Americas.

Launch of a new anti-parasitic

Vermax[®], launched by Vétoquinol in France in August 2010, is a new anti-parasitic that provides a complete solution for controlling parasites in cattle farms. Vermax[®] is highly effective against a broad spectrum of parasites that reduce productivity in cattle.

"The steady growth in Vétoquinol's revenues, despite the general weakness in the European animal health market, reflects the strength and diversity of our product portfolio and the effectiveness of Vétoquinol's marketing and sales teams in the field," said Matthieu Frechin, CEO of Vétoquinol. "In addition, we are actively developing new products that will be launched in the course of 2011."

About Vétoquinol

Vétoquinol is an independent veterinary pharmaceutical laboratory serving both the companion and production animal markets. This family-owned group, dedicated exclusively to animal health, is the 10th largest animal healthcare laboratory in the world. More than 80% of its revenues are generated outside France.

Vétoquinol's business includes research and development, production and marketing of medicinal and non-medicinal products. Vétoquinol has positioned itself in the curative sector and has developed expertise in three therapeutic fields: anti-infectives, pain/inflammation and cardiology/nephrology.

The Group currently distributes its products in more than one hundred countries throughout Europe, North America and Asia/Pacific, with subsidiaries in 23 countries and a network of 140 distribution partners. The company has more than 1,550 employees worldwide.

For more information: www.vetoquinol.com.

OUR BUSINESS: ANIMALS. OUR ADVANTAGE: PEOPLE.

For more information, contact:

VETOQUINOL

Finance department
Marie-Josée AUBRY-ROTA
Tel.: +33 (0)3 84 62 59 88
relations.investisseurs@vetoquinol.com

KEIMA COMMUNICATION

Investor relations
Emmanuel DOVERGNE
Tel.: +33 (0)1 56 43 44 63
emmanuel.dovergne@keima.fr

Media relations
Sibylle DESCAMPS
Tel.: +33 (0)1 56 43 44 72
sibylle.descamps@keima.fr

ANNEX

Revenues, in thousands of euros	2010	2009	Change	Change with exchange rates held constant	Change with exchange rates and scope of business held constant
1 st quarter	64,478	57,110	+12.9%	+10.4%	+5.4%
2 nd quarter	73,517	62,771	+17.1%	+11.5%	+6.8%
3 rd quarter	68,869	62,168	+10.8%	+5.2%	+4.1%
Total for the 9 months	206,864	182,049	+13.6%	+9.0%	+5.4%